DREDGECAP
NASDAQ·Biological Products, (No Diagnostic Substances)

BIIBBIOGEN INC.

Last filing: 8-K·May 14, 2026EDGAR ↗
Active risk signals
No active risk_flag rows for BIIB. DredgeCap's extractor pipeline runs daily; new signals appear as the underlying SEC filings drop.
XBRL

Key financials

Revenue
$2.48B
+1.9%Mar 31, 2026
Net Income (Loss)
$319.50M
+32.8%Mar 31, 2026
Operating Cash Flow
$645.50M
+148.9%Mar 31, 2026
Cash & Equivalents
$3.38B
+30.2%Mar 31, 2026
Total Assets
$29.48B
+5.2%Mar 31, 2026
Total Liabilities
$10.83B
+2.0%Mar 31, 2026

Values sourced directly from SEC XBRL filings. YoY arrows compare the latest reported period to the same period one year prior on the same reporting concept.

Recent SEC filings

View all →
FormDateAccessionEDGAR
8-KMay 14, 20260001193125-26-222908view ↗
10-QApr 29, 20260000875045-26-000045view ↗
8-KApr 29, 20260000875045-26-000042view ↗
8-KApr 6, 20260000875045-26-000039view ↗
8-KMar 31, 20260001193125-26-134889view ↗
8-KMar 11, 20260000950157-26-000280view ↗
10-KFeb 6, 20260000875045-26-000013view ↗
10-QOct 30, 20250000875045-25-000049view ↗
10-QJul 31, 20250000875045-25-000033view ↗
10-QMay 1, 20250000875045-25-000018view ↗

Related on BIIB

Auditor & opinion
Who signs off and how long they've served.
Share-count dilution
Outstanding shares + ATM + convertible activity.
Going-concern history
Auditor + management language across filings.
All filings
Full cached SEC filing history for this ticker.
All figures sourced verbatim from SEC EDGAR via XBRL. DredgeCap does not synthesize, estimate, or extrapolate dollar amounts. Risk-flag categories are derived from cited filing language. Not financial advice.